A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Trial Profile

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ZUMA-3
  • Sponsors Kite Pharma
  • Most Recent Events

    • 06 Mar 2018 Planned number of patients changed from 75 to 100.
    • 12 Dec 2017 Results from phase I part of the study (Data cut off: 26 April, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 Results presented in a Kite Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top